期刊
IUBMB LIFE
卷 57, 期 9, 页码 639-644出版社
WILEY
DOI: 10.1080/15216540500264588
关键词
GABA; gamma-hydroxybutyric acid; succinic semialdehyde dehydrogenase deficiency; knockout mice; epilepsy; oxidative damage; pharmacotherapy
资金
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040270] Funding Source: NIH RePORTER
- NINDS NIH HHS [NS 40270] Funding Source: Medline
Murine models of inborn errors of metabolism represent an established approach for investigating pathophysiological mechanisms associated with the corresponding human disorder. Our laboratory studies human inherited defects of GABA synthesis and degradation. One of these, succinate semialdehyde dehydrogenase (SSADH) deficiency (or gamma-hydroxybutyric aciduria; OMIM 271980; E.C. 1.2.1.24), has recently been modeled via gene targeting in the mouse. SSADH(-/-) mice succumb to early lethality in status epilepticus at postnatal (PN) days 20-26. Numerous metabolic, neurochemical and neurophysiological abnormalities have been documented using in vitro and in vivo approaches, substantially altering our thoughts about the complexity of the corresponding human condition. Moreover, novel preclinical treatment paradigms have been developed through drug trials in gene-ablated animals. The greatest utility of this animal, however, may reside in its transition from early absence seizures to generalized convulsions and eventual status epilepticus. Accurate neurochemical assessment during this transition may provide clues to the same transition process in patients, for which the underlying mechanisms remain undefined.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据